Kona Medical

High-Level Overview

Kona Medical, Inc. is a medical technology company developing the Surround Sound® Hypertension Therapy System, a non-invasive ultrasound-based treatment for hypertension through renal denervation (RDN).[1][2][3] It targets patients with resistant high blood pressure uncontrolled by medication, serving cardiologists and hypertension specialists by offering a one-time procedure that avoids radiation, contrast media, catheters, or catheterization labs, reducing costs and complexity while showing promising blood pressure reductions in trials.[1][2]

Founded as a privately held startup in the Bellevue/Issaquah, Washington area with under 25 employees and revenue below $5 million, Kona has raised over $60 million from leading medtech investors, including a $10 million round for expansion into China.[1][2]

Origin Story

Kona Medical was founded in 2009 (with some sources noting 2010) by Michael Gertner, MD, a physician-entrepreneur motivated by the unmet need in treating resistant hypertension, where medications fail for many patients.[1][2][4] Gertner identified renal nerves near the renal arteries as key regulators of blood pressure and pioneered focused ultrasound (FUS) for their non-invasive ablation, evolving from early Doppler guidance to full ultrasound imaging for targeting and tracking without skin puncture.[2]

Early traction included clinical trials demonstrating safety and efficacy, with backing from top medtech investors enabling over $60 million in funding; a pivotal shift was advancing to a 50-patient study fully outside cath labs.[2] The company emerged from University of Washington-affiliated innovation ecosystems, humanizing its story as a clinician-led push against invasive RDN alternatives.[6]

Core Differentiators

Kona stands out in hypertension therapy through these key advantages:

• Fully non-invasive procedure: Uses external ultrasound for imaging, robotic guidance, and focused energy delivery to ablate renal nerves, eliminating catheters, radiation, or labs—unlike competitors requiring invasive access.[1][2][3]
• Surround Sound® technology: Delivers broad ultrasound coverage to treat large tissue volumes quickly from behind the patient, minimizing skin risks and enabling outpatient simplicity.[1][2]
• Superior safety and efficiency: Trials show significant, lasting blood pressure drops with an excellent profile; reduces procedural complexity and costs.[1][2]
• Technical innovations: Overcame challenges like transducer fitting, respiration tracking, and vessel imaging for precise, puncture-free RDN.[2]

Role in the Broader Tech Landscape

Kona rides the focused ultrasound (FUS) wave in medtech, targeting the $50B+ hypertension market where 1 in 3 adults suffer and ~10-15% have resistant cases unresponsive to drugs.[2] Timing aligns with post-SYMPLICITY trial validation of RDN (2010s), but Kona disrupts by making it non-invasive amid rising demand for minimally invasive cardiology amid aging populations and medtech convergence with AI-guided imaging.[1][2]

Market forces favor it: regulatory progress (e.g., FDA pathways), China expansion for scale, and investor interest in outpatient shifts post-COVID; it influences ecosystems by advancing FUS platforms for soft-tissue treatments beyond hypertension, like other nerve ablations.[2][6]

Quick Take & Future Outlook

Kona's next milestones include completing the 50-patient non-invasive study, consolidating into a commercial system, and launching U.S. FDA trials—potentially positioning it for global RDN dominance if data confirms broad efficacy.[2] Trends like FUS maturation, value-based care favoring low-cost outpatient therapies, and AI enhancements for precision will propel it, evolving its influence from hypertension pioneer to broader neuromodulation leader in a non-invasive medtech surge.

This clinician-founded innovator exemplifies how targeted ultrasound can redefine chronic disease management, tying back to its core mission of simplifying hypertension control.